Roquefort Therapeutics (LON:ROQ) Shares Down 15.2% – Time to Sell?

Roquefort Therapeutics plc (LON:ROQ) was down 15.2% on Tuesday . The company traded as low as GBX 1.48 ($0.02) and last traded at GBX 1.60 ($0.02). Approximately 6,200,585 shares traded hands during trading, an increase of 221% from the average daily volume of 1,934,276 shares. The stock had previously closed at GBX 1.89 ($0.02).

Roquefort Therapeutics Stock Down 4.7 %

The firm has a market cap of £1.94 million, a price-to-earnings ratio of -1.26 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The firm’s fifty day moving average is GBX 3.22 and its two-hundred day moving average is GBX 3.72.

Insiders Place Their Bets

In other news, insider Stephen Paul West purchased 400,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were bought at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,249.71). 60.40% of the stock is owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.